Tag Archives: Lemtrada™ (alemtuzumab) for multiple sclerosis

Sanofi and its subsidiary Genzyme announced positive interim results from the second year of the extension study of Lemtrada™ (alemtuzumab) for multiple sclerosis

Posted on 15, September 2014 by

In approximately 70 percent of patients, disability scores improved or remained stable for an additional two years beyond the two-year pivotal multiple sclerosis studies Approximately 70 percent of patients treated with Lemtrada did not receive a third course of treatment … Read the full press release →

Posted in France, Healthcare, Pharma & Biotech

Tagged , ,